HC Wainwright Brokers Increase Earnings Estimates for AMLX

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for Amylyx Pharmaceuticals in a report released on Wednesday, March 4th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.34) for the quarter, up from their previous forecast of ($0.40). HC Wainwright currently has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.93) EPS, FY2029 earnings at $1.83 EPS and FY2030 earnings at $3.93 EPS.

Several other research firms have also weighed in on AMLX. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Bank of America lifted their target price on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Stifel Nicolaus started coverage on shares of Amylyx Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $21.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.56.

Amylyx Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:AMLX opened at $13.85 on Friday. The company has a market cap of $1.53 billion, a P/E ratio of -8.94 and a beta of -0.31. The company’s fifty day moving average is $13.94 and its two-hundred day moving average is $13.22. Amylyx Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of large investors have recently bought and sold shares of AMLX. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the fourth quarter valued at about $25,000. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $45,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after acquiring an additional 3,493 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares during the last quarter. 95.84% of the stock is currently owned by institutional investors.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 136,193 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the sale, the chief executive officer directly owned 3,378,621 shares in the company, valued at $45,915,459.39. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Karen Firestone purchased 8,100 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average price of $12.45 per share, for a total transaction of $100,845.00. Following the purchase, the director owned 63,100 shares in the company, valued at $785,595. The trade was a 14.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders sold 151,203 shares of company stock valued at $2,028,385. 12.30% of the stock is currently owned by company insiders.

More Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi‑year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer‑term upside.
• Positive Sentiment: Avexitide remains the company’s key near‑term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well‑funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near‑term profitability remains a multi‑quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near‑term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.